CarrièresEspace presseCOVID-19
  1. Home
  2. Laboratory Diagnostics
  3. Assays by Diseases and Conditions
  4. Liver Fibrosis Assays 
  5. Turn the tide against the liver's silent killer – NASH
Doctor with Blood Tube

Introducing a non-invasive blood test for advanced liver fibrosis due to NASH

As many as 4 to 6 million people are projected to have advanced fibrosis due to NASH1

By 2030, NASH (non-alcoholic steatohepatitis) is predicted to be the #1 leading indication for liver transplant.1,2 Our Enhanced Liver Fibrosis (ELF™) Test is the first blood test granted De Novo marketing authorization by the FDA for prognosis in advanced fibrosis due to NASH.

Meet a few Siemens Healthineers colleagues working to help turn the tide against the liver's silent killer – NASH

Want to know more about our innovations? Join us for the AACC 2021 Virtual Experience.

Register

The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.

1

Estes C, Razavi H, Loomba, R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-3

2

Younossi ZM, et al. Global Epidemiology of Nonalcoholic Fatty Liver Disease—Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes Hepatology. 2016;64(1): 73-84